Ribomic, Inc. (JP:4591)
:4591
Want to see JP:4591 full AI Analyst Report?
Top Page
Ribomic, Inc.
(4591)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥61.00
▼(-18.67% Downside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by sustained unprofitability and continued cash burn, despite the benefit of a debt-free balance sheet. Technically, the stock is in a clear downtrend (below key moving averages) with oversold momentum indicators that may limit near-term downside but do not reverse the broader weakness. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Debt-free balance sheet
Zero total debt and a net-cash posture materially lower near-term financing risk and provide a durable buffer to support ongoing R&D and collaborations. This structural strength buys runway for 2–6 months+ of development activities without immediate refinancing stress.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicate structural cash burn to fund R&D and operations. Over 2–6 months this necessitates financing or partner income; absent reliable inflows, cash depletion threatens continuity or forces dilutive funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero total debt and a net-cash posture materially lower near-term financing risk and provide a durable buffer to support ongoing R&D and collaborations. This structural strength buys runway for 2–6 months+ of development activities without immediate refinancing stress.
Read all positive factors
Ribomic, Inc. (4591) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.41B
Dividend YieldN/A
Average Volume (3M)477.44K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth42.38%
EPS Growth8.81%
CountryJP
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.34
Shares Outstanding55,972,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ribomic, Inc. Business Overview & Revenue Model
Company Description
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related mac...
How the Company Makes Money
Ribomic primarily generates revenue through licensing agreements, collaborative research partnerships, and milestone payments from pharmaceutical companies. It develops aptamer-based drug candidates and seeks commercial partnerships for their deve...
Ribomic, Inc. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 607.00K | 3.00M | 2.11M | 0.00 | 65.97M | 80.91M |
| Gross Profit | 173.00K | 0.00 | 1.19M | -10.50M | 0.00 | 0.00 |
| EBITDA | -1.02B | -1.20B | -1.05B | -1.11B | -1.79B | -1.73B |
| Net Income | -992.53M | -1.15B | -1.02B | -1.02B | -1.65B | -1.68B |
Balance Sheet | ||||||
| Total Assets | 2.93B | 2.98B | 3.19B | 3.55B | 4.58B | 4.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.81B | 2.83B | 3.04B | 3.40B | 4.33B | 4.70B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.84M | 135.09M | 142.21M | 155.81M | 199.30M | 260.53M |
| Stockholders Equity | 2.82B | 2.84B | 3.04B | 3.39B | 4.38B | 4.69B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.12B | -1.03B | -955.48M | -1.73B | -1.51B |
| Operating Cash Flow | 0.00 | -1.11B | -996.97M | -932.76M | -1.71B | -1.50B |
| Investing Cash Flow | 0.00 | 289.83M | 67.18M | 177.27M | 276.35M | 689.56M |
| Financing Cash Flow | 0.00 | 911.05M | 667.26M | 27.65M | 1.33B | 354.72M |
Ribomic, Inc. Technical Analysis
Negative
75.00
Price Trends
75.14
Negative
82.28
Negative
85.94
Negative
Market Momentum
-4.13
Negative
33.69
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Negative. The current price of 75 is above the 20-day moving average (MA) of 65.65, below the 50-day MA of 75.14, and below the 200-day MA of 85.94, indicating a bearish trend. The MACD of -4.13 indicates Negative momentum. The RSI at 33.69 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4591.
Ribomic, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥4.70B | -1.45 | ― | 5.44% | -16.97% | -517.61% | |
45 Neutral | ¥3.41B | -2.92 | ― | ― | 42.38% | 8.81% | |
45 Neutral | ¥8.32B | -8.41 | -26.70% | ― | 60.80% | -8.89% | |
45 Neutral | ¥11.24B | -9.75 | ― | ― | ― | 24.17% | |
41 Neutral | ¥124.61B | -36.31 | -10.16% | ― | -59.19% | -124.16% |
* Healthcare Sector Average
JP:4591
Ribomic, Inc.
61.00
-43.00
-41.35%
JP:4587
Peptidream
959.80
-641.20
-40.05%
JP:4571
NanoCarrier Co., Ltd.
100.00
-50.00
-33.33%
JP:2183
Linical Co., Ltd.
208.00
-100.47
-32.57%
JP:4575
CanBas Co., Ltd.
570.00
-354.00
-38.31%
Ribomic, Inc. Corporate Events
Ribomic Widens Losses but Boosts Liquidity as It Projects Deeper Red Ink
May 14, 2026
Ribomic reported non-consolidated operating revenue of ¥3 million for the year ended March 31, 2026, up from ¥2 million a year earlier, but continued to post losses, with operating loss widening to ¥1,207 million and net loss at ...
RIBOMIC Files IND for Phase III Trial of Achondroplasia Drug in Japan
Mar 19, 2026
RIBOMIC has submitted an IND application to Japan’s Pharmaceuticals and Medical Devices Agency for a Phase III clinical trial of umedaptanib pegol in pediatric patients aged 2 to 14 with achondroplasia, a rare genetic disorder that causes sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.